Plasma levels of clusterin are associated with early atrophy in the EC and the clinical progression of AD (Thambisetty et al., 2010), and clusterin has been identified as a genetic determinant of AD in a genome-wide study (Lambert et al., 2009). This evidence concerns the gene CLU and Alzheimer disease.